Sun Pharmaceutical Industries (SUNPHARMA) Investor presentation summary

Business overview and global presence

• Operates in over 100 countries with a diversified portfolio including specialty, branded generics, generics, and APIs.

• Largest pharmaceutical company in India and 12th largest in the US generics market.

• 40 manufacturing facilities across six continents, with many approved by global regulators.

• Employs over 43,000 people worldwide.

• Expanding presence in developed and emerging markets outside the US.

Financial performance and growth

• FY25 sales reached Rs 520 Bn, with a 19% CAGR in sales from FY10 to FY25.

• EBITDA margin at 29% and adjusted net profit margin at 22.8% for FY25.

• Market capitalization of US $46 Bn as of July 2025.

• Free cash flow CAGR of 24% from FY10 to FY25.

• Strong return ratios: ROCE at 20.4% and ROE at 17.4% in FY25.

Revenue composition and business segments

• India formulations contribute 33%, US formulations 31%, emerging markets 18%, ROW 14%, and API & others 4% of FY25 sales.

• Specialty and innovative therapies account for over 20% of total sales.

• US business is the 12th largest generics player, with a robust pipeline and 659 ANDAs filed.

• India business leads with 8.3% market share and top ranking in 13 prescriber categories.

• Emerging markets and ROW have a strong presence with local manufacturing and extensive branded generics portfolio.